Comparison of buserelin and nafarelin in IVF cycles and in subsequent frozen-thawed embryo transfer cycles.

Simberg N, Tulppala M, Husa LM, Tiitinen A

Acta obstetricia et gynecologica Scandinavica1 Sept 1998Cited by 6 (Europe PMC)

PMID9776601DOI10.1080/j.1600-0412.1998.770813.xPepBankPUB-09776601

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanRandomized controlled trialEfficacy outcome
In IVF patients, median LH after two weeks was higher with nafarelin, 2.6 versus 1.8 IU/L with buserelin (p=0.0001).
In plain wordsLH after two weeks was higher with nafarelin than buserelin.
Peptide
Nafarelin
Outcome
IncreaseSerum LH after two weeks
Study
n = 181
Comparator
Buserelin
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
800 microg/day · intranasalAs given in this study (human).
Measurements
Median LH
2.6 IU/L
nafarelin
LH lower quartile
1.8 IU/L
nafarelin
LH upper quartile
4 IU/L
nafarelin
Median LH
1.8 IU/L
buserelin
LH lower quartile
1.3 IU/L
buserelin
LH upper quartile
2.4 IU/L
buserelin
Source sentences
Summary
Serum LH was lower after two weeks on buserelin: 1.8 (1.3-2.4) IU/L (median, with lower and upper quartile in parenthesis), than after nafarelin: 2.6 (1.8-4.0) IU/L, (p=0.0001).
1 context sentence(design, population, supporting numbers)
Summary · context
Infertility patients (n=181) were randomized to receive buserelin (1200 microg/day, n=90) or nafarelin (800 microg/day, n=91) intranasally starting in the luteal phase.
Report a problemFND-0977660101
02HumanRandomized controlled trialEfficacy outcome
In IVF patients, no other serum hormone differences were detected between nafarelin and buserelin.
In plain wordsNo other serum hormone differences were detected between nafarelin and buserelin.
Peptide
Nafarelin
Outcome
No significant changeOther serum hormone differences
Study
n = 181
Comparator
Buserelin
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
800 microg/day · intranasalAs given in this study (human).
Source sentences
Summary
No other differences in serum hormone levels could be detected.
2 context sentences(design, population, supporting numbers)
Summary · context
Serum levels of LH, estradiol and progesterone were measured during the treatment.
Summary · context
Infertility patients (n=181) were randomized to receive buserelin (1200 microg/day, n=90) or nafarelin (800 microg/day, n=91) intranasally starting in the luteal phase.
Report a problemFND-0977660102
03HumanRandomized controlled trialEfficacy outcome
In IVF patients, median oocyte recovery was lower with nafarelin, 11.0 versus 13.0 with buserelin (p=0.046).
In plain wordsFewer oocytes were recovered with nafarelin than buserelin.
Peptide
Nafarelin
Outcome
DecreaseOocytes recovered
Study
n = 181
Comparator
Buserelin
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
800 microg/day · intranasalAs given in this study (human).
Measurements
Median oocytes
11 oocytes
nafarelin
Lower quartile oocytes
6.8 oocytes
nafarelin
Upper quartile oocytes
15 oocytes
nafarelin
Median oocytes
13 oocytes
buserelin
Lower quartile oocytes
8 oocytes
buserelin
Upper quartile oocytes
19 oocytes
buserelin
Source sentences
Summary
More oocytes were recovered in the buserelin group: 13.0 (8.0-19.0) vs 11.0 (6.8-15.0), (p=0.046), but the fertilization rate was higher in the nafarelin group (49.9%, vs 45.1%, p=0.023).
1 context sentence(design, population, supporting numbers)
Summary · context
Infertility patients (n=181) were randomized to receive buserelin (1200 microg/day, n=90) or nafarelin (800 microg/day, n=91) intranasally starting in the luteal phase.
Report a problemFND-0977660103
04HumanRandomized controlled trialEfficacy outcome
In IVF patients, fertilization was higher with nafarelin, 49.9% versus 45.1% with buserelin (p=0.023).
In plain wordsFertilization rates were higher with nafarelin than buserelin.
Peptide
Nafarelin
Outcome
IncreaseFertilization rate
Study
n = 181
Comparator
Buserelin
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
800 microg/day · intranasalAs given in this study (human).
Measurements
Fertilization rate
49.9%
nafarelin
Fertilization rate
45.1%
buserelin
Source sentences
Summary
More oocytes were recovered in the buserelin group: 13.0 (8.0-19.0) vs 11.0 (6.8-15.0), (p=0.046), but the fertilization rate was higher in the nafarelin group (49.9%, vs 45.1%, p=0.023).
1 context sentence(design, population, supporting numbers)
Summary · context
Infertility patients (n=181) were randomized to receive buserelin (1200 microg/day, n=90) or nafarelin (800 microg/day, n=91) intranasally starting in the luteal phase.
Report a problemFND-0977660104
05HumanRandomized controlled trialEfficacy outcome
In IVF patients, implantation was higher with nafarelin, 26.28% versus 15.5% with buserelin (p=0.030).
In plain wordsImplantation rates were higher with nafarelin than buserelin in initial IVF cycles.
Peptide
Nafarelin
Outcome
IncreaseImplantation rate in initial IVF cycles
Study
n = 181
Comparator
Buserelin
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
800 microg/day · intranasalAs given in this study (human).
Measurements
Implantation rate
26.28%
nafarelin
Implantation rate
15.5%
buserelin
Source sentences
Summary
Implantation rate was higher in the nafarelin group (26.28% vs 15.5%, p=0.030), but there were an equal number of deliveries in both groups (20.9% vs 15.6% per started stimulation, p=0.420).
1 context sentence(design, population, supporting numbers)
Summary · context
Infertility patients (n=181) were randomized to receive buserelin (1200 microg/day, n=90) or nafarelin (800 microg/day, n=91) intranasally starting in the luteal phase.
Report a problemFND-0977660105
06HumanRandomized controlled trialEfficacy outcome
Delivery rates were 20.9% with nafarelin versus 15.6% with buserelin per started stimulation, without a significant difference (p=0.420).
In plain wordsDelivery rates were numerically higher with nafarelin than buserelin, without a significant difference.
Peptide
Nafarelin
Outcome
IncreaseDelivery rate per started stimulation
Study
n = 181
Comparator
Buserelin
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
800 microg/day · intranasalAs given in this study (human).
Measurements
Delivery rate
20.9%
nafarelin per started stimulation
Delivery rate
15.6%
buserelin per started stimulation
Source sentences
Summary
Implantation rate was higher in the nafarelin group (26.28% vs 15.5%, p=0.030), but there were an equal number of deliveries in both groups (20.9% vs 15.6% per started stimulation, p=0.420).
1 context sentence(design, population, supporting numbers)
Summary · context
Infertility patients (n=181) were randomized to receive buserelin (1200 microg/day, n=90) or nafarelin (800 microg/day, n=91) intranasally starting in the luteal phase.
Report a problemFND-0977660106
07HumanRandomized controlled trialEfficacy outcome
Subsequent frozen-thawed transfer implantation rates were 21.1% with prior nafarelin versus 10.6% with prior buserelin (p=0.067).
In plain wordsImplantation after frozen-thawed transfer was numerically higher with prior nafarelin than buserelin, without statistical significance.
Peptide
Nafarelin
Outcome
IncreaseImplantation rate in frozen-thawed transfer cycles
Study
n: not reported in source
Comparator
Buserelin
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
800 microg/day · intranasalAs given in this study (human).
Measurements
Implantation rate
21.1%
nafarelin
Implantation rate
10.6%
buserelin
Source sentences
Summary
In the subsequent frozen-thawed embryo transfer cycles the implantation rate was 21.1% (nafarelin group) and 10.6% (buserelin group, p=0.067), the pregnancy rate/ET was 31.7% and 17.0% (p=0.107) and the delivery rate was 22.0% and 10.6% (p=0.148), respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Infertility patients (n=181) were randomized to receive buserelin (1200 microg/day, n=90) or nafarelin (800 microg/day, n=91) intranasally starting in the luteal phase.
Report a problemFND-0977660107
08HumanRandomized controlled trialEfficacy outcome
Subsequent frozen-thawed transfer pregnancy rates were 31.7% with prior nafarelin versus 17.0% with prior buserelin (p=0.107).
In plain wordsPregnancy after frozen-thawed transfer was numerically higher with prior nafarelin than buserelin, without statistical significance.
Peptide
Nafarelin
Outcome
IncreasePregnancy rate per frozen-thawed embryo transfer
Study
n: not reported in source
Comparator
Buserelin
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
800 microg/day · intranasalAs given in this study (human).
Measurements
Pregnancy rate per ET
31.7%
nafarelin
Pregnancy rate per ET
17%
buserelin
Source sentences
Summary
In the subsequent frozen-thawed embryo transfer cycles the implantation rate was 21.1% (nafarelin group) and 10.6% (buserelin group, p=0.067), the pregnancy rate/ET was 31.7% and 17.0% (p=0.107) and the delivery rate was 22.0% and 10.6% (p=0.148), respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Infertility patients (n=181) were randomized to receive buserelin (1200 microg/day, n=90) or nafarelin (800 microg/day, n=91) intranasally starting in the luteal phase.
Report a problemFND-0977660108
09HumanRandomized controlled trialEfficacy outcome
Subsequent frozen-thawed transfer delivery rates were 22.0% with prior nafarelin versus 10.6% with prior buserelin (p=0.148).
In plain wordsDelivery after frozen-thawed transfer was numerically higher with prior nafarelin than buserelin, without statistical significance.
Peptide
Nafarelin
Outcome
IncreaseDelivery rate in frozen-thawed transfer cycles
Study
n: not reported in source
Comparator
Buserelin
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
800 microg/day · intranasalAs given in this study (human).
Measurements
Delivery rate
22%
nafarelin
Delivery rate
10.6%
buserelin
Source sentences
Summary
In the subsequent frozen-thawed embryo transfer cycles the implantation rate was 21.1% (nafarelin group) and 10.6% (buserelin group, p=0.067), the pregnancy rate/ET was 31.7% and 17.0% (p=0.107) and the delivery rate was 22.0% and 10.6% (p=0.148), respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Infertility patients (n=181) were randomized to receive buserelin (1200 microg/day, n=90) or nafarelin (800 microg/day, n=91) intranasally starting in the luteal phase.
Report a problemFND-0977660109

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.